The Latin America, Middle East and Africa Guillain-Barre Syndrome Market would witness market growth of 6.2% CAGR during the forecast period (2023-2030).
The Brazil market dominated the LAMEA Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $15,320.9 Thousands by 2030. The Argentina market is registering a CAGR of 7.1% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 5.9% during (2023 - 2030).
Cerebrospinal fluid (CSF) analysis lumbar puncture is performed to obtain CSF samples for analysis, including cell counts, protein levels, and the presence of inflammatory markers such as elevated protein levels without an increase in white blood cells, indicative of albumin cytologic dissociation, a hallmark of GBS.
Additionally, magnetic resonance imaging (MRI) of the spine and nerve roots may reveal characteristic findings such as nerve root enhancement, nerve enlargement, or spinal cord abnormalities, supporting the diagnosis of GBS and ruling out other neurological conditions.
The World Health Organization (WHO) reports that 130 suspected cases of GBS were reported in Peru between June 10, 2023, and July 15, 2023. 44 of these cases have been verified. The number of instances observed has increased more than anticipated. Additionally, 231 probable GBS cases were reported in Peru between epidemiological weeks 1 and 28 (until July 15, 2023). Thus, the rising aging population and increasing healthcare expenditure in the LAMEA region propel the market’s growth.
Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Guillain-Barre Syndrome Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $15,320.9 Thousands by 2030. The Argentina market is registering a CAGR of 7.1% during (2023 - 2030). Additionally, The UAE market would showcase a CAGR of 5.9% during (2023 - 2030).
Cerebrospinal fluid (CSF) analysis lumbar puncture is performed to obtain CSF samples for analysis, including cell counts, protein levels, and the presence of inflammatory markers such as elevated protein levels without an increase in white blood cells, indicative of albumin cytologic dissociation, a hallmark of GBS.
Additionally, magnetic resonance imaging (MRI) of the spine and nerve roots may reveal characteristic findings such as nerve root enhancement, nerve enlargement, or spinal cord abnormalities, supporting the diagnosis of GBS and ruling out other neurological conditions.
The World Health Organization (WHO) reports that 130 suspected cases of GBS were reported in Peru between June 10, 2023, and July 15, 2023. 44 of these cases have been verified. The number of instances observed has increased more than anticipated. Additionally, 231 probable GBS cases were reported in Peru between epidemiological weeks 1 and 28 (until July 15, 2023). Thus, the rising aging population and increasing healthcare expenditure in the LAMEA region propel the market’s growth.
Based on Therapeutics, the market is segmented into Intravenous Immunoglobulin, Plasma Exchange, and Others. Based on Route of Administration, the market is segmented into Parenteral, and Oral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- F.Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Market Report Segmentation
By Therapeutics- Intravenous Immunoglobulin
- Plasma Exchange
- Others
- Parenteral
- Oral
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA Guillain-Barre Syndrome Market by Therapeutics
Chapter 5. LAMEA Guillain-Barre Syndrome Market by Route Of Administration
Chapter 6. LAMEA Guillain-Barre Syndrome Market by Distribution Channel
Chapter 7. LAMEA Guillain-Barre Syndrome Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- F. Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- PTC, Inc.
- AstraZeneca PLC
- Novartis AG
- Novo Nordisk A/S
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Merck & Co., Inc.
- Bristol Myers Squibb Company
Methodology
LOADING...
